InsidersTradesSigma
Track the Poseida Therapeutics, Inc. stock price and the full management transaction log of the company, a publicly traded company based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Poseida Therapeutics, Inc. has recorded 83 public disclosures. The latest transaction was reported on 10 January 2025 (U). Among the most active insiders: Ostertag Eric. The full history is accessible without an account.
83
Insider Decl.
n/a
Thresholds
€8m
9 ops.
Buy Volume
€1m
9 ops.
Sell Volume
25Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 10 January 2025
Declarations83 total
11,835,673 sharesCOMMON STOCKSEC:0001104659-25-002540:0
58,950 sharesCommon StockSEC:0001415889-25-001089:0
58,950 sharesCommon StockSEC:0001415889-25-001090:0
68,950 sharesCommon StockSEC:0001415889-25-001087:0
58,950 sharesCommon StockSEC:0001415889-25-001086:0
185,000 sharesCommon StockSEC:0001415889-25-001083:0
636,726 sharesCommon StockSEC:0001415889-25-001081:0
223,640 sharesCommon StockSEC:0001415889-25-001082:0
615,836 sharesCommon StockSEC:0001415889-25-001080:0
58,950 sharesCommon StockSEC:0001415889-25-001088:0
254,852 sharesCommon StockSEC:0001415889-25-001084:0
78,600 sharesCommon StockSEC:0001415889-25-001085:0
23,313 shares@ US$9.6025.2% of flowCommon StockSEC:0000950170-25-001527:0
30,000 shares@ US$2.7819.2% of flowCommon StockSEC:0000950170-24-135466:0
30,000 shares@ US$2.7819.3% of flowCommon StockSEC:0000950170-24-131665:0
19,650 shares0Common StockSEC:0000950170-24-074865:0
19,650 shares0Common StockSEC:0000950170-24-074862:0
19,650 shares0Common StockSEC:0000950170-24-074873:0
19,650 shares0Common StockSEC:0000950170-24-074864:0
19,650 shares0Common StockSEC:0000950170-24-074875:0
19,650 shares0Common StockSEC:0000950170-24-074872:0
185,000 shares0Common StockSEC:0000950170-24-041039:0
80,743 shares0Common StockSEC:0000950170-24-024921:0
80,743 shares0Common StockSEC:0000950170-24-024920:0
34,157 shares@ US$4.1315.2% of flowCommon StockSEC:0000950170-24-024922:0
25 of 83 declarations
关于 Poseida Therapeutics, Inc.
Poseida Therapeutics, Inc. (股票代码：PSTX) 是一家美国生物技术公司，在纳斯达克上市，作为一家临床阶段的细胞和基因疗法开发商运营。Poseida 成立于 2014 年，通过公司重组和从 Transposagen Biopharmaceuticals 剥离而来，其业务围绕专有的非病毒基因工程平台构建，并将总部设在美国主要的生物技术中心加利福尼亚州圣迭戈。([sec.gov](https://www.sec.gov/Archives/edgar/data/1661460/000095017024027998/pstx-20231231.htm?utm_source=openai)) 从运营角度来看，Poseida 专注于开发针对高度未满足医疗需求的疗法，特别是血液系统癌症，其更广泛的管线沟通中还包括实体瘤、罕见病以及最近的自身免疫相关项目。其核心技术栈围绕三个差异化平台：piggyBac 非病毒 DNA 递送系统、Cas-CLOVER 位点特异性基因编辑平台以及基于纳米颗粒和 AAV 的递送技术。这些能力使公司成为异体细胞疗法和体内基因药物领域的专家。([sec.gov](https://www.sec.gov/Archives/edgar/data/1661460/000095017024027998/pstx-20231231.htm?utm_source=openai)) 在竞争方面，Poseida 最著名的是追求现成的异体 CAR-T 疗法，并高度重视干细胞记忆 T 细胞 (TSCM)。这种方法旨在相对于早期细胞疗法概念提供更好的持久性、效力和安全性。2024 年，该公司强调了 P-BCMA-ALLO1 治疗多发性骨髓瘤的进展，并公布了其更广泛的细胞疗法管线的临床前和早期临床更新。它还受益于与罗氏和武田的战略合作，这些合作验证了该平台，同时有助于分担开发风险。([poseida.com](https://poseida.com/news/poseida-therapeutics-highlights-positive-interim-phase-1-results-for-p-bcma-allo1-and-preclinical-data-for-dual-car-t-p-cd19cd20-allo1-at-the-66th-american-society-of-hematology-ash-annual-meeting/?utm_source=openai)) 最近最重要的进展是罗氏于 2024 年底同意收购 Poseida，随后在 2025 年初进行了要约收购流程并接受了要约股票。罗氏表示，此次收购建立在异体 CAR-T 疗法现有合作的基础上。对于投资者而言，这意味着 PSTX 不再被视为一个独立的公开生物技术故事；相反，其价值主张与罗氏的所有权、交易完成机制以及任何或有价值权利挂钩，而非传统的公开市场增长叙事。([roche.com](https://www.roche.com/investors/updates/inv-update-2024-11-26b?utm_source=openai))
